Investor Presentaiton
Strong track record
Unique model
Large moat
Significant opportunity
Our competitive position has strengthened since our IPO
Compounding growth
Pre-IPO
Today
Increase
Private
~$24bn
Public market value
Equity ownership structure(1)
Business
model
Debt portfolio weighted average maturity
5.5 years
Announced deal value (prior 2 years) (2)
12.5 years
Depth &
Accessibility
>2.0x
$2.8bn
$5.2bn
1.8x
Scale
Cash flow streams acquired (prior 2 years) (2)
11
20
20
In-depth opportunity reviews (3)
40
40
Platform
Full time employees (4)
IPO: initial public offering
1. Market data as of May 13, 2022.
35
1.8x
61
1.5x
66
1.9x
2. Total announced value of transactions excluding equity for the pre-IPO period Q3 2018 through Q2 2020. Total announced value of transactions excluding equity for the today period includes
Q3 2020 through Q2 2022.
ROYALTY PHARMA
3. In-depth opportunity reviews for the pre-IPO period represents 2019. In-depth opportunity reviews for the today period represents 2021. IPO was June 2020.
4. Full-time employees for the pre-IPO period is as of December 31, 2019; full-time employees for the today period is as of December 31, 2021.
15View entire presentation